Wakamoto Pharmaceutical Co.,Ltd.
Research Wakamoto Pharmaceutical Co.,Ltd. (4512.T) on Bullrun: market cap JPY 10.52B, P/E 30.7, dividend yield 1.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4512.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyJPY
- Market capJPY 10.52B
- P/E30.7
- Dividend yield1.2%
- Financial periodFY2026
- RevenueJPY 9.91B
- Revenue growth27.2%
- Net incomeJPY 227.22M
- Free cash flow-JPY 1.14B
- Gross margin47.7%
Valuation Snapshot
latest market cap is JPY 10.52B; P/E is 30.7; dividend yield is 1.2%.
Peer valuation comparison
Latest P/E is 30.67x versus a Healthcare sector median of 21.69x (41.4% above).
Latest dividend yield is 1.17% versus a Healthcare sector median of 2.41% (51.5% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 9.91B | JPY 227.22M | -JPY 1.14B | 47.7% | 6.54 | JPY 2.01B | JPY 400.00M | JPY 12.01B |
| FY2025 | JPY 7.79B | JPY 64.44M | -JPY 1.09B | 46.5% | 1.85 | JPY 2.95B | JPY 128.56M | JPY 11.61B |
| FY2024 | JPY 7.74B | JPY 108.96M | -JPY 701.95M | 46.5% | 3.13 | JPY 3.66B | JPY 130.73M | JPY 12.03B |
| FY2023 | JPY 8.66B | JPY 138.26M | JPY 420.76M | 47.4% | 3.98 | JPY 3.88B | JPY 137.79M | JPY 11.91B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 10.52B | 30.7 | 1.2% | 3.5 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 3.5 JPY, yield 1.2%.
| Year | Dividends/share |
|---|---|
| FY2026 | 3.5 JPY |
| FY2025 | 3 JPY |
| FY2024 | 3 JPY |
| FY2023 | 3 JPY |
About Wakamoto Pharmaceutical Co.,Ltd.
Wakamoto Pharmaceutical Co.,Ltd. is engaged in the manufacture and sale of pharmaceuticals, medical devices, and health food in Japan. It operates through four segments: Pharmaceutical Business, Healthcare Business, Global Business, and Real Estate Leasing Business. The company offers Strong and Granule Wakamoto, gastrointestinal drugs for digestion, intestinal regulation, and nutritional supplementation, as well as Wakamoto Intestinal Remedy drug.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Wakamoto Pharmaceutical Co.,Ltd.'s market cap?
Wakamoto Pharmaceutical Co.,Ltd.'s market capitalization is JPY 10.52B.
What is Wakamoto Pharmaceutical Co.,Ltd.'s P/E ratio?
Wakamoto Pharmaceutical Co.,Ltd.'s price-to-earnings (P/E) ratio is 30.7.
Does Wakamoto Pharmaceutical Co.,Ltd. pay a dividend?
Wakamoto Pharmaceutical Co.,Ltd. has a dividend yield of 1.2%.
What does Wakamoto Pharmaceutical Co.,Ltd. do?
Wakamoto Pharmaceutical Co.,Ltd. is engaged in the manufacture and sale of pharmaceuticals, medical devices, and health food in Japan. It operates through four segments: Pharmaceutical Business, Healthcare Business, Global Business, and Real Estate Leasing Business. The company offers Strong and Granule Wakamoto, gastrointestinal drugs for digestion, intestinal regulation, and nutritional supplementation, as well as Wakamoto Intestinal Remedy drug. It also provides AVANTBISE oral tablets, a supplement of bacteria to restore the balance of oral flora; and medicated toothpaste.